KR950000728A - 포스포네이트 뉴클레오티드 에스테르 유도체 - Google Patents

포스포네이트 뉴클레오티드 에스테르 유도체 Download PDF

Info

Publication number
KR950000728A
KR950000728A KR1019940015180A KR19940015180A KR950000728A KR 950000728 A KR950000728 A KR 950000728A KR 1019940015180 A KR1019940015180 A KR 1019940015180A KR 19940015180 A KR19940015180 A KR 19940015180A KR 950000728 A KR950000728 A KR 950000728A
Authority
KR
South Korea
Prior art keywords
group
compound
formula
atom
ring
Prior art date
Application number
KR1019940015180A
Other languages
English (en)
Other versions
KR100358327B1 (ko
Inventor
히데아끼 다까시마
나오꼬 이노우에
마사루 우바사와
고오이찌 세끼야
싱고 야부우찌
Original Assignee
미야베 요시가즈
미쓰비시 가세이 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미야베 요시가즈, 미쓰비시 가세이 가부시기가이샤 filed Critical 미야베 요시가즈
Publication of KR950000728A publication Critical patent/KR950000728A/ko
Application granted granted Critical
Publication of KR100358327B1 publication Critical patent/KR100358327B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

아래의 일반식(I)으로 나타내어지는 포스포네이트 뉴클레오티드 에스테르 유도체 또는 그 염.
위의 식에서 환 A :
R1,R2: H,할로겐 원자, OH, 아미노기 등, R3: 저급 알킬기, 치환 에틸기, R4: 치환 에틸기.
(효과) 본 발명의 포스포네이트 뉴클레오티드 에스테르 유도체는 우수한 항비루스 활성과 항종양 활성을 가지며, 더욱이 경구 투여가 가능하다.

Description

포스포네이트 뉴클레오티드 에스테르 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 아래의 일반식(I)으로 나타내어지는 포스포네이트 뉴클레오티드 에스테르 유도체 또는 그 염.
    위의 일반식(I)에서, 환(環) A는 아래의 구조식을 나타내고,
    R1과 R2는 각각 독립하여 수소 원자, 할로겐 원자, 히드록실기, 메르캅토기, C6~C10의 아릴티오기 또는 아미노기를 나타내고, R3는 C1~C4의 알킬기 또는 플루오르 원자, C1~C4의 알콕시기, 페녹시기, C7~C10의 페닐알콕시기 및 C2~C5의 아실옥시기로부터 선택되는 하나 이상의 치환기를 가진 에틸기를 나타내며, R4는 플루오르 원자, C1~C4의 알콕시기, 페녹시기, C7~C10의 페닐알콕시기 및 C2~C5의 아실옥시기로부터 선택되는 하나 이상의 치환기를 가진 에틸기를 나타내고, X,Y 및 Z는 각각 독립하여 메틴기 또는 질소원자를 나타낸다.
  2. 제1항에 있어서, 환 A가 아래의 구조식인 화합물.
    위의 식에서 R1과 R2는 제1항에서 정의한 바와 같다.
  3. 제1항에 있어서, 환 A가 아래의 구조식인 화합물.
    위의 식에서 R1은 수소 원자, 히드록실기, 메르캅토기, 톨릴티오기 또는 아미노기를 나타내고, R2는 수소 원자, 염소 원자, 요오드 원자, 히드록실기 또는 아미노기를 나타낸다.
  4. 제1항에 있어서, 환 A가 아래의 구조식인 화합물.
    위의 식에서 R1은 아미노기를 나타내고, R2는 수소 원자를 나타낸다.
  5. 제1항에 있어서, 환 A가 아래의 구조식인 화합물.
    위의 식에서 R1과 R2는 아미노기를 나타낸다.
  6. 제1항 내지 제5항에 있어서, R3가 C1~C3의 알킬기, 2,2,2-트리플루오로에틸기 또는 C1~C3의 알콕시기, 페녹시기, C7~C10의 페닐알콕시기 및 C2~C5의 아실옥시기로부터 선택되는 치환기를 하나 가진 에틸기인 화합물.
  7. 제1항 내지 제5항에 있어서, R3가 C1~C3의 알킬기 또는 2,2,2-트리플루오로에틸기인 화합물.
  8. 제1항 내지 제7항에 있어서, R4가 2,2,2-트리플루오로에틸기 또는 C1~C3의 알콕시기, 페녹시기, C7~C10의 페닐알콕시기 및 C2~C5의 아실옥시기로부터 선택되는 치환기를 하나 가진 에틸기인 화합물.
  9. 제1항 내지 제7항에 있어서, R4가 2,2,2-트리플루오로에틸기인 화합물.
  10. 제1항 내지 제9항에 있어서, X 및 Z가 질소 원자인 화합물.
  11. 제1항 내지 제10항에 기재된 화합물 및 약학적으로 허용되는 담체를 함유하여서 되는 의약 조성물.
  12. 제1항 내지 제10항에 기재된 화합물을 유효성분으로 하는 항비루스제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940015180A 1993-06-29 1994-06-29 포스포네이트뉴클레오티드에스테르유도체 KR100358327B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP93-159693 1993-06-29
JP15969393 1993-06-29

Publications (2)

Publication Number Publication Date
KR950000728A true KR950000728A (ko) 1995-01-03
KR100358327B1 KR100358327B1 (ko) 2003-03-03

Family

ID=15699257

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940015180A KR100358327B1 (ko) 1993-06-29 1994-06-29 포스포네이트뉴클레오티드에스테르유도체

Country Status (8)

Country Link
US (1) US6037335A (ko)
EP (1) EP0632048B1 (ko)
KR (1) KR100358327B1 (ko)
CN (1) CN1040761C (ko)
AT (1) ATE199906T1 (ko)
CA (1) CA2126601A1 (ko)
DE (1) DE69426904T2 (ko)
TW (1) TW302366B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970015804A (ko) * 1995-09-28 1997-04-28 이웅열 저수축 나일론 6 필라멘트사 및 그의 제조방법

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
EP0702556B1 (en) * 1993-06-10 2002-10-23 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
EP0719274A1 (en) * 1993-09-17 1996-07-03 Gilead Sciences, Inc. Method for dosing therapeutic compounds
WO1996006620A2 (en) 1994-08-29 1996-03-07 Wake Forest University Lipid analogs for treating viral infections
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US6197775B1 (en) * 1995-06-15 2001-03-06 Mitsubishi Chemical Corporation Phosphonate nucleotide derivatives
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
TW369536B (en) * 1996-01-18 1999-09-11 Mitsubishi Chem Corp Phosphonate nucleotide compounds
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
WO1998006726A1 (fr) 1996-08-13 1998-02-19 Mitsubishi Chemical Corporation Composes nucleotidiques a base de phosphonate
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
BR9811045A (pt) * 1997-07-25 2000-08-22 Gilead Sciences Inc Composição de análogo de nucleotìdeo e processo de sìntese
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
DK1256584T3 (da) * 1997-07-25 2004-12-06 Gilead Sciences Inc Fremgangsmåde til fremstilling af adefovir-dipivoxil
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
PT1256584E (pt) * 1997-07-25 2004-12-31 Gilead Sciences Inc Processo para a preparacao de adefovir-dipivoxil
AU761267C (en) * 1998-09-09 2007-08-09 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
CA2393410C (en) 1999-12-03 2011-10-11 Karl Y. Hostetler Phosphonate compounds
EP1914237B1 (en) 1999-12-03 2014-06-18 The Regents of The University of California Phosphonate ester antiviral compounds
JP2003519154A (ja) * 1999-12-22 2003-06-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なビスアミダートホスホネートプロドラッグ
KR20020093824A (ko) * 2000-02-29 2002-12-16 미쯔비시 웰 파마 가부시키가이샤 포스포네이트 뉴클레오티드 화합물
CN1699383A (zh) 2000-03-08 2005-11-23 症变治疗公司 新的芳基果糖－1,6－二磷酸酶抑制剂
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
MY141789A (en) * 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
US20030114467A1 (en) * 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
WO2003028737A1 (en) * 2001-08-30 2003-04-10 Mitsubishi Pharma Corporation Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
US7551837B2 (en) 2001-08-31 2009-06-23 Thomson Licensing Sequence counter for an audio visual stream
KR20050044587A (ko) * 2001-12-07 2005-05-12 미쯔비시 웰 파마 가부시키가이샤 Ｂ형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도
BR0309557A (pt) 2002-04-26 2005-03-01 Gilead Sciences Inc Inibidores da transcriptase reversa não nucleosìdeos
JP4476811B2 (ja) 2002-05-13 2010-06-09 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ
CA2485597C (en) * 2002-05-13 2013-07-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
CA2499889A1 (en) * 2002-09-26 2004-04-08 Lg Life Sciences Ltd. (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof
WO2004041837A1 (en) * 2002-10-31 2004-05-21 Metabasis Therapeutics, Inc. Novel cytarabine monophosphate prodrugs
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
AU2004233897A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US20050080053A1 (en) * 2003-08-29 2005-04-14 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
EP1678321A1 (en) 2003-10-24 2006-07-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
GB0326168D0 (en) * 2003-11-10 2003-12-17 Arrow Therapeutics Ltd Chemical compounds
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
NZ547907A (en) 2003-12-22 2010-07-30 Gilead Sciences Inc 4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
AR048021A1 (es) * 2004-02-17 2006-03-22 Anadys Pharmaceuticals Inc Derivados nucleosido fosfonato utiles en el tratamiento de infecciones de hiv.
CN1964967B (zh) 2004-06-08 2014-04-16 症变治疗公司 路易斯酸介导的环状酯的合成
UA88313C2 (ru) 2004-07-27 2009-10-12 Гилиад Сайенсиз, Инк. Фосфонатные аналоги соединений ингибиторов вич
CN101005847A (zh) * 2004-08-18 2007-07-25 症变治疗公司 果糖1,6－双磷酸酶的新颖噻唑类抑制剂
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007014491A1 (fr) * 2005-08-03 2007-02-08 Beijing Fu Kang Ren Bio-Pharm Tech.Co.Ltd. Phosphonates de nucléotides acycliques et leur utilisation dans des agents antiviraux
WO2007058927A1 (en) 2005-11-11 2007-05-24 The Scripps Research Institute Histone deacetylase inhibitors as therapeutics for neurological diseases
KR20090026216A (ko) 2006-07-07 2009-03-11 길리애드 사이언시즈, 인코포레이티드 항바이러스 포스피네이트 화합물
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
CN101940571A (zh) 2007-04-13 2011-01-12 南方研究所 抗血管生成剂和使用方法
MX2010001784A (es) 2007-08-13 2010-03-15 Metabasis Therapeutics Inc Activadores novedosos de la glucocinasa.
EP2254582B1 (en) 2008-01-25 2016-01-20 Chimerix, Inc. Methods of treating viral infections
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
EA018308B1 (ru) 2008-07-08 2013-07-30 Джилид Сайэнс, Инк. Соли соединений ингибиторов вич
PL2799428T3 (pl) 2008-08-13 2017-05-31 Metabasis Therapeutics, Inc. Antagoniści glukagonu
WO2010078430A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
WO2011100698A2 (en) 2010-02-12 2011-08-18 Chimerix, Inc. Methods of treating viral infection
WO2011133963A2 (en) * 2010-04-23 2011-10-27 University Of Southern California Tyrosine-based prodrugs of antiviral agents
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES
KR101880724B1 (ko) 2010-12-10 2018-08-17 시그마팜 래보러토리즈, 엘엘씨 경구 활성 뉴클레오티드 유사체 또는 경구 활성 뉴클레오티드 유사체 전구약물의 고 안정성 조성물
US9550803B2 (en) 2011-05-06 2017-01-24 University Of Southern California Method to improve antiviral activity of nucleotide analogue drugs
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
CN102786549B (zh) * 2012-08-13 2013-07-03 洛阳聚慧投资股份有限公司 一组具有抑制hiv-1病毒复制活性的替诺福韦双酯化合物、制备方法及其药物用途
LT2970346T (lt) 2013-03-15 2018-11-26 The Regents Of The University Of California Acikliniai nukleozido fosfonato diesteriai
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN103819472A (zh) * 2014-03-18 2014-05-28 福建天泉药业股份有限公司 缬恩替卡韦酸式加成盐及其制备方法
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
RS63250B1 (sr) * 2014-09-15 2022-06-30 Univ California Nukleotidni analozi
US10377782B2 (en) 2015-09-15 2019-08-13 The Regents Of The University Of California Nucleotide analogs
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
GB9026164D0 (en) * 1990-12-01 1991-01-16 Beecham Group Plc Pharmaceuticals
TW369536B (en) * 1996-01-18 1999-09-11 Mitsubishi Chem Corp Phosphonate nucleotide compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970015804A (ko) * 1995-09-28 1997-04-28 이웅열 저수축 나일론 6 필라멘트사 및 그의 제조방법

Also Published As

Publication number Publication date
US6037335A (en) 2000-03-14
TW302366B (ko) 1997-04-11
EP0632048B1 (en) 2001-03-21
EP0632048A1 (en) 1995-01-04
ATE199906T1 (de) 2001-04-15
CN1106017A (zh) 1995-08-02
CN1040761C (zh) 1998-11-18
CA2126601A1 (en) 1994-12-30
DE69426904D1 (de) 2001-04-26
DE69426904T2 (de) 2001-10-11
KR100358327B1 (ko) 2003-03-03

Similar Documents

Publication Publication Date Title
KR950000728A (ko) 포스포네이트 뉴클레오티드 에스테르 유도체
KR940007022A (ko) 피패리딘 유도체, 이것의 제법 및 치료에 있어서 이것의 이용
ATE174899T1 (de) Zytotoxische stilben-derivate und diese enthaltende pharmazeutische zusammensetzungen
KR900004735A (ko) 시클로부탄 유도체 및 그 제조방법
KR960034164A (ko) 스틸벤 유도체 및 이를 함유하는 약제학적 조성물
KR890011601A (ko) (사이클로알킬아미노)메틸렌비스(포스폰산)및 활성성분으로서 이를 함유한 의약
KR930703303A (ko) 1, 4-벤조티아제핀 유도체
KR890011902A (ko) 디데옥시디데히드로카르보시클릭 뉴클레오시드
KR900002778A (ko) 학습력 또는 기억력 증진제
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
KR910005859A (ko) 항종양제
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
KR960700245A (ko) 메토트렉세이트 유도체[methotrexate derivative]
FI853866A0 (fi) 2-pyridin-tiol-derivat, foerfarande foer framstaellning av dessa samt farmaceutiska foereningar innehaollande dessa.
KR930023031A (ko) 아졸 유도체를 함유하는 항아로마타제제
KR970704463A (ko) 스트렙토그라민 유도체, 이의 제조 방법 및 이를 함유하는 약학 조성물(streptogramine derivatives, preparation of same and pharmaceutical compositions containing same)
KR950011530A (ko) 사이클로프로판 유도체 및 이를 함유하는 항바이러스제
KR890005087A (ko) 4- 피페리딘 카르복사미드 유도체
KR970061875A (ko) 신규 항바이러스성 6위치에 치환된 피리미딘디온 호모 카보사이클릭 뉴클레오시드 유도체 및 그의 제조 방법
KR930019210A (ko) 메일라드반응 억제개선제
KR930017906A (ko) 술포닐벤질 치환 이미다조피리딘
KR950018033A (ko) 뉴클레오시드 화합물 및 이의 제조방법
KR970070006A (ko) 2-아미노-6-플루오로-9-(2-하이드록시에톡시메틸)퓨린 에스테르 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20051004

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee